infectious disease, drug development

Multiple candidates are in Phase 3 clinical trials for older adults and pregnant women, with some getting close to approval in the United States.

Both Pfizer and GSK have shared preliminary data suggesting that their experimental vaccines can protect older adults and newborn infants from the virus.

In clinical trials, the new inoculation demonstrated greater protection for children and people older than 45 than the existing dengue vaccine.

Launched with a $172 million philanthropic donation and funds from the state of Victoria, the Melbourne-based research institute aims to construct drug discovery platforms to speed the introduction of new therapies.

The results could help guide the design of new vaccines for the disease.

It’s unclear how long protections against infection will last from the initial vaccinations, and health authorities say additional jabs will likely be necessary.

As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.

A recent study elucidates some of the changes that occur in the body after inoculation with a tuberculosis vaccine.

As researchers test existing vaccines for nonspecific protection against COVID-19, immunologists are working to understand how some inoculations protect against pathogens they weren’t designed to fend off.

Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.

Some researchers express skepticism given the lack of data about the vaccine’s safety and efficacy, and the country plans to vaccinate healthcare workers, teachers, and others even before testing is complete.

Despite high-profile political tensions between the two countries, researchers in the US and China are working together now more than ever, according to our bibliometric study.

Find the latest updates in this one-stop resource, including efficacy data and side effects of approved shots, as well as progress on new candidates entering human studies.

The drug, called memantine, could enter clinical trials to determine its effectiveness in humans.

The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.